Tempus AI, Inc. (NASDAQ:TEM) CEO Sells $17,517,500.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Eric P. Lefkofsky sold 250,000 shares of Tempus AI stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $70.07, for a total value of $17,517,500.00. Following the sale, the chief executive officer now owns 9,357,283 shares of the company's stock, valued at approximately $655,664,819.81. This trade represents a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Tempus AI Stock Performance

NASDAQ:TEM traded down $2.66 during trading hours on Monday, hitting $65.65. 10,350,086 shares of the company were exchanged, compared to its average volume of 7,107,445. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.71 and a quick ratio of 1.56. Tempus AI, Inc. has a 52-week low of $22.89 and a 52-week high of $91.45. The stock has a market capitalization of $11.37 billion and a price-to-earnings ratio of -8.42. The company's 50 day moving average price is $58.73 and its 200-day moving average price is $52.70.

Tempus AI (NASDAQ:TEM - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.03. The firm had revenue of $255.74 million for the quarter, compared to the consensus estimate of $248.13 million. Tempus AI had a negative return on equity of 533.21% and a negative net margin of 88.27%. The firm's revenue was up 75.4% on a year-over-year basis. As a group, research analysts forecast that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on TEM. Wolfe Research downgraded Tempus AI from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Needham & Company LLC reissued a "buy" rating and set a $70.00 target price on shares of Tempus AI in a research report on Wednesday, May 7th. JPMorgan Chase & Co. cut shares of Tempus AI from an "overweight" rating to a "neutral" rating and upped their price target for the stock from $50.00 to $55.00 in a research report on Tuesday, February 25th. William Blair reissued a "market perform" rating on shares of Tempus AI in a report on Tuesday, February 25th. Finally, Guggenheim restated a "buy" rating on shares of Tempus AI in a report on Tuesday, February 25th. Six analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $63.42.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Voya Investment Management LLC purchased a new stake in shares of Tempus AI in the 1st quarter valued at $1,717,000. Rhumbline Advisers acquired a new position in Tempus AI during the first quarter valued at $116,000. Strs Ohio purchased a new stake in Tempus AI in the first quarter valued at $1,718,000. Arete Wealth Advisors LLC purchased a new stake in Tempus AI in the first quarter valued at $314,000. Finally, Temasek Holdings Private Ltd acquired a new stake in Tempus AI during the 1st quarter worth about $360,000. 24.22% of the stock is owned by institutional investors and hedge funds.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.